|
000
| 01644cam 22002898a 4500 |
|---|
| 001 | 9.865656 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107161841 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 181205t20192014onc #o f000 0 eng d |
|---|
| 020 | |a9780660288628 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP40-243/2018E-PDF |
|---|
| 245 | 00|aLiterature review on the immunogenicity of herpes zoster vaccines |h[electronic resource]. |
|---|
| 260 | |a[Ottawa] : |bPublic Health Agency of Canada, |c2019. |
|---|
| 300 | |a46 p. |
|---|
| 500 | |aIssued also in French under title: Revue de la littérature sur l'immunogénicité des vaccins contre le zona. |
|---|
| 500 | |a"Publication date: January 2019." |
|---|
| 500 | |a"An Advisory Committee Review (ACR), National Advisory Committee on Immunization (NACI)." |
|---|
| 500 | |aCover title. |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 520 | |a"Herpes zoster is an acute viral infection caused by reactivation of varicella-zoster virus (VZV). LZV, a live, attenuated vaccine for zoster has been available in Canada for many years. A new subunit recombinant zoster vaccine (RZV) named Shingrix was approved in Canada in October 2017. This zoster vaccine immunogenicity review was done to have a comprehensive understanding of the immunogenicity of both live and subunit vaccines"--Executive summary, p. 3. |
|---|
| 692 | 07|2gccst|aImmunization |
|---|
| 710 | 2 |aPublic Health Agency of Canada. |
|---|
| 775 | 08|tRevue de la littérature sur l'immunogénicité des vaccins contre le zona |w(CaOODSP)9.865657 |
|---|
| 856 | 40|qPDF|s1.56 MB|uhttps://publications.gc.ca/collections/collection_2019/aspc-phac/HP40-243-2018-eng.pdf |
|---|